Adrenal Insufficiency Treatment Market Forecast Booming by Size, Revenue, Trend and Top Growing Companies 2027

Admin

5 years ago

Deficiency of hormones secreted by the adrenal gland including cortisol and aldosterone due to congenital or acquired disorders is known as adrenal insufficiency. Some of the symptoms of adrenal insufficiency include fatigue, muscle weakness, low appetite, weight loss, and belly pain. Adrenal insufficiency is of three types: Primary, Secondary, and Tertiary.

Primary adrenal insufficiency is when your adrenal glands are damaged and can’t make the cortisol you need. This condition is often called Addison’s disease. The secondary adrenal insufficiency is found to be more common than primary adrenal insufficiency and can occur due to a number of genetic factors; pituitary tumors; surgery or irradiation for pituitary tumors; tumors outside the HPA axis or leukemia; infections such as hemochromatosis; tuberculosis; and meningitis; pituitary apoplexy; or necrosis.
Tertiary adrenal insufficiency occurs due to deficiency of a hormone called corticotropin-releasing hormone (CRH) which is secreted from the hypothalamus and tells the pituitary to make ACTH. When the hypothalamus is not making enough CRH, it affects the pituitary’s ability to produce ACTH, thereby keeping the adrenal glands from producing enough cortisol.

Increase in awareness regarding timely diagnosis of congenital disorders is likely to propel the adrenal insufficiency treatment market during the forecast period. Increasing risk of trauma cases due to a number of factors such as road injuries, war-related trauma, other accidents, and increasing global disease burden, acquired adrenal insufficiency is anticipated to grow at a faster pace during the forecast period.
Demand for development of newer and technologically enhanced products is rising globally, owing to the treatment efficiency of drugs. Hence, major players operating in the market are investing in research & development programs in order to develop new drugs.

Get PDF Sample Copy of Report: (Including TOC, List of Tables & Figures, Chart) : https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=76571

Current oral glucocorticoid replacement therapy for patients with adrenal insufficiency (AI) does not truly mimic the normal physiologic cortisol rhythm, a nadir at bedtime and gradually rising levels to the early morning peak between 3 am and 6 am before waking.
Continuous subcutaneous hydrocortisone infusion therapy administered via an insulin pump to deliver hydrocortisone is another novel method for the treatment of adrenal insufficiency. All these factors are anticipated to drive the global adrenal insufficiency market during the forecast period.
However, poor reimbursement, high cost of treatment, and various side effects associated with drugs may hamper the market growth

The global adrenal insufficiency treatment market can be segmented based on indication, source, treatment type, distribution channel, and region
In terms of indication, the global adrenal insufficiency treatment market can be divided into primary, secondary, and tertiary adrenal insufficiency. Secondary adrenal insufficiency is projected to be the fastest growing segment of adrenal insufficiency treatment market.
On the basis of source, the market can be segmented into acquired and congenital
In terms of treatment type, the market is segmented into glucocorticoids, corticotropin, and others
Based on distribution channel, the global adrenal insufficiency treatment market can be classified into hospital pharmacies, retail pharmacies, and online pharmacies

The global adrenal insufficiency treatment market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
Improving health care infrastructure, rising awareness about timely diagnosis of underlying disorders such as adrenal insufficiency, and large patient population are anticipated to present significant opportunities to adrenal insufficiency treatment market in Asia Pacific in the near future. Increase in public and private health care expenditure in countries such as China and India is expected to attract manufacturers toward these markets.

Leading players in the global adrenal insufficiency treatment market include:

North America
- U.S.
- Canada
Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Australia & New Zealand
- Rest of Asia Pacific
Latin America
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa
- GCC Countries
- South Africa
- Rest of Middle East & Africa